Centessa Pharmaceuticals (NASDAQ:CNTA) Research Coverage Started at TD Cowen

TD Cowen started coverage on shares of Centessa Pharmaceuticals (NASDAQ:CNTA) in a report published on Tuesday, MarketBeat Ratings reports. The firm issued a buy rating on the stock.

Other equities analysts also recently issued research reports about the stock. Guggenheim lifted their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. BMO Capital Markets lifted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. B. Riley initiated coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 target price on the stock. Jefferies Financial Group raised their price target on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, September 11th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $11.00 to $26.00 in a research note on Thursday, September 19th. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Centessa Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $16.10 on Tuesday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a fifty day simple moving average of $16.98 and a two-hundred day simple moving average of $14.33. Centessa Pharmaceuticals has a 1-year low of $6.65 and a 1-year high of $18.97. The firm has a market cap of $2.12 billion, a price-to-earnings ratio of -10.52 and a beta of 1.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. Analysts anticipate that Centessa Pharmaceuticals will post -1.6 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In related news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $17.04, for a total value of $170,400.00. Following the transaction, the insider now directly owns 183,266 shares in the company, valued at approximately $3,122,852.64. This represents a 5.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Saurabh Saha sold 1,671 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The shares were sold at an average price of $18.24, for a total transaction of $30,479.04. Following the completion of the sale, the chief executive officer now directly owns 575,661 shares in the company, valued at $10,500,056.64. This represents a 0.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 368,023 shares of company stock valued at $6,335,574. 11.59% of the stock is currently owned by company insiders.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently made changes to their positions in CNTA. First Light Asset Management LLC raised its position in Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of Centessa Pharmaceuticals by 27.6% during the 2nd quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock valued at $35,518,000 after purchasing an additional 850,000 shares during the last quarter. FMR LLC raised its holdings in shares of Centessa Pharmaceuticals by 4.6% during the 3rd quarter. FMR LLC now owns 2,916,494 shares of the company’s stock valued at $46,635,000 after buying an additional 129,300 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Centessa Pharmaceuticals by 54.1% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock worth $43,423,000 after buying an additional 953,659 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Centessa Pharmaceuticals by 99.1% in the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock worth $38,360,000 after buying an additional 1,145,823 shares during the last quarter. 82.01% of the stock is owned by institutional investors.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.